Insulin + oral glucose-lowering medications or GLP-1 receptor agonists

Insulin + oral glucose-lowering medications or GLP-1 receptor agonists has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest story, Nov 12, 2026: “Early type 2 diabetes diagnosis linked to higher death rates”.

Intervention

1 paper studies it1 findingUpdated Nov 12, 2026

1 new paper in 30 daysSee all 1 papers on insulin + oral glucose-lowering medications or GLP-1 receptor agonists

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Insulin alone and combined with oral glucose-lowering medications or glucagon-like peptide-1 receptor agonists were associated with increased mortality”

All-cause mortality and associated factors according to age at diagnosis of type 2 diabetes in FinlandBMJ open diabetes research & care2026doi:10.1136/bmjdrc-2026-006329

1 lab in 1 country

Humans1

What is insulin + oral glucose-lowering medications or GLP-1 receptor agonists linked with?

Studies link insulin + oral glucose-lowering medications or GLP-1 receptor agonists with mortality.

Mortality

upin humans1RR 1.63

1 study

Insulin + oral glucose-lowering medications or GLP-1 receptor agonists are associated with mortality in humans (type 2 diabetes) (RR 1.63, 95% CI 1.52 to 1.75).
“Insulin alone and combined with oral glucose-lowering medications or glucagon-like peptide-1 receptor agonists were associated with increased mortality”
Humanstype 2 diabetes2018 to 2023
Early type 2 diabetes diagnosis linked to higher death rates
BMJ open diabetes research & careNov 12, 2026

Latest

1 paper in 12 months

BMJ Open Diabetes Research & CareNov 12

Early type 2 diabetes diagnosis linked to higher death rates

With 100 representing expected mortality based on Finns without diabetes, death ratios were 288 for diagnosis by 40 and 56 at 80 or older.With 100 representing expected mortality based on Finns without diabetes, death ratios were 288 for diagnosis by 40 and 56 at 80 or older.

Cohort · 485,713 peopleType 2 diabetes

Paper